newsfilter
← Latest News
PR Newswire·

Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update

NEW YORK, June 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced an update on its ongoing National Institutes of Health ("NIH"